Del Carmen Jeffrey sold (to issuer) $452K of CPRX
Del Carmen Jeffrey (Chief Commercial Officer) sold (to issuer) 14,337 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($0.45M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The disclosure updates insider ownership (post-transaction holdings: 0 shares) but does not provide new company performance, trial, regulatory, or financial guidance information.
Market read
Traders may note the insider reduced exposure at a specific price, but the event is unlikely to drive a fundamental repricing by itself.
What to watch
No 10b5-1 plan is indicated, but the filing still lacks context on taxes, diversification, or compensation mechanics; without additional filings, signal is weak.
Background
The filing is an SEC Form 4 insider transaction by the company’s Chief Commercial Officer.
Ticker impact
Catalyst Pharmaceuticals CCO Del Carmen Jeffrey sold 14,337 shares to the issuer at $31.50 on 2026-07-15, totaling $451,615.50.
Likely limited near-term impact; treat as low-signal unless paired with other disclosures.
Form 4 provides a concrete transaction size and price, but insider sales to the issuer are often mechanical and the filing does not include new operational or guidance information.
Market effects
No direct read-across to biotech sector fundamentals from a single insider sale.
None.
None.
Counterpoint
The sale is to the issuer and may be part of a structured program (e.g., buyback participation), so it may not reflect bearish views.
Key entities
- issuerCatalyst Pharmaceuticals, Inc.
CPRX, the company whose insider transaction is disclosed on Form 4.
- insiderDel Carmen Jeffrey
Chief Commercial Officer who sold 14,337 shares to the issuer at $31.50.